II 

110TH CONGRESS 

1ST SESSION S. 30 

To intensify research to derive human pluripotent stem cell lines. 

IN THE SENATE OF THE UNITED STATES 

MARCH 29, 2007 

Mr. COLEMAN (for himself and Mr. ISAKSON) introduced the following bill; 

which was read twice and ordered held at the desk 

A BILL 

To intensify research to derive human pluripotent stem cell 

lines. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Hope Offered through 

5 Principled and Ethical Stem Cell Research Act’’ or the 

6 ‘‘HOPE Act’’. 

7 SEC. 2. PURPOSES. 

8 It is the purpose of this Act to— 

9 (1) intensify research that may result in im10 proved understanding of or treatments for diseases 

11 and other adverse health conditions; and 


ccoleman on PROD1PC60 with BILLS
2 

•S 30 HDS

1 (2) promote the derivation of pluripotent stem 

2 cell lines without the creation of human embryos for 

3 research purposes and without the destruction or 

4 discarding of, or risk of injury to, a human embryo 

5 or embryos other than those that are naturally dead. 

6 SEC. 3. HUMAN PLURIPOTENT STEM CELL RESEARCH. 

7 Part H of title IV of the Public Health Service Act 

8 (42 U.S.C. 289 et seq.) is amended by inserting after sec9 tion 498C the following: 

10 ‘‘SEC. 498D. HUMAN PLURIPOTENT STEM CELL RESEARCH. 

11 ‘‘(a) IN GENERAL.—The Secretary shall conduct and 

12 support basic and applied research to develop techniques 

13 for the isolation, derivation, production, or testing of stem 

14 cells, including pluripotent stem cells that have the flexi15 bility of embryonic stem cells (whether or not they have 

16 an embryonic source), that may result in improved under17 standing of or treatments for diseases and other adverse 

18 health conditions, provided that the isolation, derivation, 

19 production, or testing of such cells will not involve— 

20 ‘‘(1) the creation of a human embryo or em21 bryos for research purposes; or 

22 ‘‘(2) the destruction or discarding of, or risk of 

23 injury to, a human embryo or embryos other than 

24 those that are naturally dead. 


ccoleman on PROD1PC60 with BILLS
3 

•S 30 HDS

1 ‘‘(b) GUIDELINES.—Not later than 90 days after the 

2 date of the enactment of this section, the Secretary, after 

3 consultation with the Director of NIH, shall issue final 

4 guidelines that— 

5 ‘‘(1) provide guidance concerning the next steps 

6 required for additional research, which shall include 

7 a determination of the extent to which specific tech8 niques may require additional animal research to en9 sure that any research involving human cells using 

10 these techniques would clearly be consistent with the 

11 standards established under subsection (a); 

12 ‘‘(2) prioritize research with the greatest poten13 tial for near-term clinical benefit; 

14 ‘‘(3) consistent with standards established 

15 under subsection (a), take into account techniques 

16 outlined by the President’s Council on Bioethics and 

17 any other appropriate techniques and research; and 

18 ‘‘(4) in the case of research involving stem cells 

19 from a naturally dead embryo, require assurances 

20 from grant applicants that no alteration of the tim21 ing, methods, or procedures used to create, main22 tain, or intervene in the development of a human 

23 embryo was made solely for the purpose of deriving 

24 the stem cells. 


ccoleman on PROD1PC60 with BILLS
4 

•S 30 HDS

1 ‘‘(c) REPORTING REQUIREMENTS.—Not later than 

2 January 1 of each year, the Secretary shall prepare and 

3 submit to the appropriate committees of the Congress a 

4 report describing the activities carried out under this sec5 tion during the fiscal year, including a description of the 

6 research conducted under this section. 

7 ‘‘(d) RULE OF CONSTRUCTION.—Nothing in this sec8 tion shall be construed as altering the policy in effect on 

9 the date of enactment of this section regarding the eligi10 bility of stem cell lines for funding by the National Insti11 tutes of Health. 

12 ‘‘(e) AUTHORIZATION OF APPROPRIATIONS.—There 

13 is authorized to be appropriated such sums as may be nec14 essary to carry out this section. 

15 ‘‘(f) DEFINITIONS.—In this section: 

16 ‘‘(1) NATURALLY DEAD.—The term ‘naturally 

17 dead’ means having naturally and irreversibly lost 

18 the capacity for integrated cellular division, growth, 

19 and differentiation that is characteristic of an orga20 nism, even if some cells of the former organism may 

21 be alive in a disorganized state. 

22 ‘‘(2) HUMAN EMBRYO OR EMBRYOS.—The term 

23 ‘human embryo or embryos’ includes any organism, 

24 not protected as a human subject under part 46 of 

25 title 45, Code of Federal Regulations, as of the date 


ccoleman on PROD1PC60 with BILLS
5 

•S 30 HDS

1 of enactment of this section, that is derived by fer2 tilization, parthenogenesis, cloning, or any other 

3 means from one or more human gametes or human 

4 diploid cells. 

5 ‘‘(3) RISK OF INJURY.—The term ‘risk of in6 jury’ means subjecting a human embryo or embryos 

7 to risk of injury or death greater than that allowed 

8 for research on fetuses in utero under section 

9 46.204(b) of title 45, Code of Federal Regulations, 

10 and section 498(b) of this Act.’’. 

11 SEC. 4. NATIONAL AMNIOTIC AND PLACENTAL STEM CELL 

12 BANK. 

13 (a) IN GENERAL.—The Secretary of Health and 

14 Human Services shall enter into a contract with the Insti15 tute of Medicine for the conduct of a study to recommend 

16 an optimal structure for an amniotic and placental stem 

17 cell bank program and to address pertinent issues to maxi18 mize the potential of such technology, including collection, 

19 storage, standards setting, information sharing, distribu20 tion, reimbursement, research, and outcome measures. In 

21 conducting such study, the Institute should receive input 

22 from relevant experts including the existing operators of 

23 federal tissue bank programs and the biomedical research 

24 programs within the Department of Defense. 


ccoleman on PROD1PC60 with BILLS
6 

•S 30 HDS

1 (b) REPORT.—Not later than 180 days after the date 

2 of enactment of this Act, the Institute of Medicine shall 

3 complete the study under subsection (a) and submit to the 

4 Secretary of Health and Human Services and the appro5 priate committees of Congress a report on the results of 

6 such study. 

Æ 


ccoleman on PROD1PC60 with BILLS